Trends in US payer management of competitive rare disease
Given that average launch prices for orphan drugs are seven times higher than those of non-orphan drugs, and with an estimated 1 in 10 Americans affected by a...
Oncology consulting with cutting-edge strategies and comprehensive expertise
The treatment, policies, and study of oncology continue to undergo rapid changes and evolution, with each year bringing new opportunities and challenges for existing and new treatments. CRA positions itself on the cutting edge of the field, staying abreast of the latest issues and developments and allowing us to provide actionable, future-focused strategies for our clients.
CRA’s knowledge base stems from hundreds of engagements on solid and hematological tumors, working with clients on small molecules, monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), cell therapies, oncology vaccines, and the increasing range of combination approaches to treating cancer.
Why CRA for your strategic partner in oncology?
Engagements
- 01Evaluating unintended impacts of the IRA’s Medicare Drug Price Negotiation Program on small and large molecule medicinesA leading pharmaceutical company sought support from CRA Life Sciences experts in analyzing the patient, health system, and innovation implications of the IRA'sView engagement
- 02Developing an evidence-based framework for sustainable NCCP funding and address global disparities in implementation and outcomesA leading pharmaceutical company sought CRA Life Sciences experts to gain a deeper understanding of how governments plan and finance national cancer strategiesView engagement
- 03Developing market-access focused segmentation and typing tool to aid uptake of bispecific oncology productsA leading pharmaceutical company sought support from CRA’s Life Sciences consultants in understanding how to best segment, target, and activate key accessView engagement